Elicio Therapeutics (ELTX) said Wednesday that three patients who received ELI-002 7P in the phase 2 Amplify-7P study and later experienced disease progression subsequently achieved complete radiographic and complete metabolic responses after receiving nivolumab-based therapy.
The company said it intends to continue monitoring additional patients who participated in the Amplify-7P study and are currently following a similar course of treatment.
Elicio said the findings support further evaluation of checkpoint inhibitor combinations and could help inform future development strategies in metastatic pancreatic ductal adenocarcinoma and the design of a planned phase 3 trial in adjuvant PDAC.
Subject to funding, the company also plans to initiate a phase 1 study evaluating ELI-002 7P in combination with gemcitabine/nab-paclitaxel chemotherapy and an anti-PD-1 inhibitor in treatment-naive metastatic mKRAS pancreatic cancer.
Price: $3.16, Change: $+0.40, Percent Change: +14.49%